HPLC methods for determination of two novel thiosemicarbazone anti-cancer drugs (N4mT and Dp44mT) in plasma and their application to in vitro plasma stability of these agents
Jazyk angličtina Země Nizozemsko Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem, validační studie
PubMed
19097949
DOI
10.1016/j.jchromb.2008.11.044
PII: S1570-0232(08)00879-9
Knihovny.cz E-zdroje
- MeSH
- analýza rozptylu MeSH
- interpretace statistických dat MeSH
- isoniazid analogy a deriváty analýza metabolismus MeSH
- králíci MeSH
- lidé MeSH
- naftaleny krev MeSH
- prasata MeSH
- protinádorové látky krev MeSH
- pyridoxal analogy a deriváty analýza metabolismus MeSH
- reprodukovatelnost výsledků MeSH
- senzitivita a specificita MeSH
- stabilita léku MeSH
- thiosemikarbazony krev MeSH
- vysokoúčinná kapalinová chromatografie metody MeSH
- zvířata MeSH
- Check Tag
- králíci MeSH
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- validační studie MeSH
- Názvy látek
- di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone MeSH Prohlížeč
- isoniazid MeSH
- N4mT agent MeSH Prohlížeč
- naftaleny MeSH
- protinádorové látky MeSH
- pyridoxal isonicotinoyl hydrazone MeSH Prohlížeč
- pyridoxal MeSH
- thiosemikarbazony MeSH
The aim of this study was to develop and validate HPLC methods for the determination in plasma of two novel thiosemicarbazone anti-tumour drugs developed in our laboratories (Dp44mT and N4mT). The appropriate separations were achieved using a HS F5 HPLC column with the mobile phase composed of a mixture of either acetate buffer/EDTA or EDTA and acetonitrile (62:38 and 50:50, v/v, respectively). The plasma samples were pretreated with SPE (phenyl and C18, respectively). Furthermore, these methods were successfully applied to in vitro plasma stability experiments. The investigation has clearly shown that both thiosemicarbazones are markedly more stable in plasma than their aroylhydrazone forerunners.
Citace poskytuje Crossref.org
